Screener
Mineralys Therapeutics, Inc. MLYS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | 2025 |
|---|---|---|
| Research and development | $24,365 | $37,879 |
| General and administrative | 20,975 | 6,568 |
| Total operating expenses | 45,340 | 44,447 |
| Loss from operations | (45,340) | (44,447) |
| Interest income, net | 5,996 | 2,239 |
| Other income (expense) | 5 | (3) |
| Total other income, net | 6,001 | 2,236 |
| Net loss | $(39,339) | $(42,211) |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s operating income?
- Mineralys Therapeutics, Inc. (MLYS) reported operating income of -$45.34M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s operating income changed year-over-year?
- Mineralys Therapeutics, Inc.'s operating income decreased by 2.0% year-over-year, from -$44.45M to -$45.34M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s operating income?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s operating income has grown at a 75.7% compound annual growth rate (CAGR), from -$31.48M to -$170.6M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Mineralys Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude